Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$82,362.00-1.52%ETH$2,534.19-1.81%GOLD$4,149.60+0.21%OIL$92.26+4.51%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACTU

Actuate Therapeutics Inc

Healthcare · Biotechnology

$0.72

Down-$0.09 (-10.77%)

Updated Oct 8, 2026, 12:16 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
86.93M
P/E ratio
-3.32
Dividend yield
0.00%
52-week range
$0.60 – $8.30
Volume
637.89K
Avg. volume
71.29K

Price performance · ACTU

ACTU price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

ACTU closed at $0.72 after 21 trading sessions, down 42.52% for the selected period.

Last close
$0.72
Period change
-42.52%
Period low
$0.62
Period high
$1.26
Daily close
View OHLC price history
ACTU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$0.6431$0.7242$0.615$0.7242637.89K
Oct 6, 2026$0.89$0.89$0.7597$0.8116337.68K
Oct 5, 2026$0.85$0.9258$0.8007$0.8749202.23K
Oct 2, 2026$0.93$0.9498$0.80$0.81996.15K
Oct 1, 2026$0.7976$0.9598$0.765$0.8892494.41K
Sep 30, 2026$0.71$0.83$0.69$0.7797410.72K
Sep 29, 2026$0.738$0.7479$0.6832$0.686112.76K
Sep 28, 2026$0.6853$0.738$0.6042$0.7362276.98K
Sep 25, 2026$0.65$0.7499$0.6401$0.68383.49K
Sep 24, 2026$0.7501$0.7501$0.6095$0.62273.38K
Sep 23, 2026$0.80$0.8692$0.72$0.7316223.24K
Sep 22, 2026$0.90$0.9302$0.80$0.8074187.23K
Sep 21, 2026$0.9869$1.02$0.89$0.9073275.52K
Sep 18, 2026$1.00$1.03$0.9601$0.9812114.38K
Sep 17, 2026$1.04$1.0499$0.9625$0.9952174.6K
Sep 16, 2026$1.00$1.05$0.94$0.9974208.83K
Sep 15, 2026$1.04$1.06$0.98$0.9837148.45K
Sep 14, 2026$1.08$1.0899$0.99$1.03259.02K
Sep 11, 2026$1.15$1.2299$1.03$1.07239.6K
Sep 10, 2026$1.25$1.28$1.13$1.15205K
Sep 9, 2026$1.38$1.3999$1.26$1.26124.42K

Latest ACTU news

The latest Smart Investors Daily articles mentioning ACTU.

Stock researchCompany · Overview

ACTU research

Overview

Company profile and research snapshot.

Company profile

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
ACTU recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Jul 30, 2026Rodman & RenshawBuy—
May 18, 2026HC Wainwright & Co.Buy—
Apr 22, 2026HC Wainwright & Co.Buy—
Apr 13, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee

Yahoo · Sep 9, 2026

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

Independent studies conducted at Northwestern University and Mayo Clinic demonstrate synergistic activity of elraglusib in combination with RAS-targeted agents across multiple murine and human pancreatic cancer modelsData further support the potential for combination therapy strategies across other RAS-driven cancers Additional studies are ongoing with results to be presented at upcoming medical conferences CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, I

Benzinga · Aug 20, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. BioVie (NASDAQ:BIVI) stock rose 30.85%

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By